drugset / Trial / NCT00577148

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

NCT00577148

Phase 3 Terminated 89 enrolled Sanofi
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the effect of rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH) in patients with Type 2 diabetes.

Timeline

Start
2008-02
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Rimonabant Small molecule 20 mg Oral

Indications